First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer

Wang, SJ; Zhu, H; Li, YJ; Ding, J; Wang, F; Ding, LX; Wang, XY; Zhao, J; Zhang, Y; Yao, YF; Zhou, T; Li, N; Wu, AW; Yang, Z

Li, N; Yang, Z (corresponding author), Peking Univ Canc Hosp & Inst, Dept Nucl Med, Beijing, Peoples R China.; Li, N; Yang, Z (corresponding author), Natl Med Prod Adm, NMPA Key Lab Res & Evaluat Radiopharmaceut, Beijing, Peoples R China.; Li, N; Wu, AW; Yang, Z (corresponding author), Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.; Wu, AW (corresponding author), Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Surg, Beijing, Peoples R China.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021; 9 (7):

Abstract

Background Death receptor 5 (DR5) is a promising therapeutic target for cancer therapy. However, many clinical trials of DR5 agonists failed to show s......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索